medigraphic.com
ISSN 0138-7103 (Print)

2016, Number 1

<< Back Next >>

Revista del Hospital Psiquiátrico de La Habana 2016; 13 (1)

CYP2D6 gene polymorphisms and their relationship to schizophrenia

Roblejo BH

Language: Spanish
References: 42
Page:
PDF size: 108.37 Kb.


ABSTRACT

Introduction: Schizophrenia is a chronic psychiatric disorder remarkably heterogeneous, marked by multiple biological alterations which influence on numerous genetic and environmental factors. Undoubtedly neuroleptics are one of the main pillars in the treatment of this condition. CYP2D6 is involved in phase I metabolism of these drugs.
Objective: To show the state of knowledge about the relationship between polymorphisms of the CYP2D6 gene and schizophrenia.
Methods: For this review was carried out a search of articles published in PubMed / MEDLINE, which linked the frequency of CYP2D6 genotypes with schizophrenia and the risk of adverse reactions from consumption of neuroleptics. full text articles and new information on the subject were used.
slow metabolizers individuals have an increased risk of developing adverse reactions from consumption of neuroleptics risk. Moreover, although the results relating poor metabolizers genotypes with the risk of schizophrenia not match in all cases, in some research it has been identified as a protective factor for developing this disease.
Conclusions: The study of gene polymorphisms of CYP2D6 can contribute to individualized therapy in the treatment of schizophrenia.


REFERENCES

  1. 1.Chen J, Cao F, Liu L, Wang L, Chen X. Genetic studies of schizophrenia: an update. Neuroscience bulletin. 2015;31(1):87-98.

  2. Catalán J, Romero F, Miranda C, Roco A, Saavedra I. Metabolismo de los antipsicóticos: enzimas y genes relacionados. Rev Farmacol Chile. 2011;4(1):15-20.

  3. 3.Haga SB, Allen LaPointe NM, Moaddeb J. Challenges to integrating pharmacogenetic testing into medication therapy management. Journal of managed care & specialty pharmacy. 2015;21(4):346-52.

  4. Roblejo Balbuena, H. Papel del citocromo CYP2D6 en la era de la farmacogenética. Rev Cubana Genet Comunit [Internet].2011[2014];3(1):URL disponible en: http://www.medigraphic.com/pdfs/revcubgencom/cgc-2011/cgc111b.pdf

  5. van der Weide K, van der Weide J. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients. Journal of clinical psychopharmacology. 2015;35(3):228-36.

  6. D'Empaire I, Guico-Pabia CJ, Preskorn SH. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant? Journal of psychiatric practice. 2011;17(5):330-9.

  7. Peñas-Lledo EM, Llerena A. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. British journal of clinical pharmacology. 2014;77(4):673-83.

  8. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta psychiatrica Scandinavica. 1993;87(1):23-8.

  9. Condra JA, Neibergs H, Wei W, Brennan MD. Evidence for two schizophrenia susceptibility genes on chromosome 22q13. Psychiatric Genetics. 2007;17(5):292-8.

  10. Kendler KS, O'Donovan MC. A breakthrough in schizophrenia genetics. JAMA psychiatry. 2014;71(12):1319-20.

  11. Takahashi S. Heterogeneity of schizophrenia: Genetic and symptomatic factors. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2013;162b(7):648-52.

  12. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003;192: 23-32.

  13. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, Roots I. The impact of the CYP2D6 polymorphim on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther. 2002;72: 438-52.

  14. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Peruca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur. J. Clin. Pharmacol.1997;51: 395-98.

  15. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenic in relation to CYP2D6 genotype. Br. J. Psychiatry.1997;170: 23-26.

  16. Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson I, Johansson I, Sjöqvist F. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenics patients. Eur. J. Clin. Pharmacol. 2000;56:679-83.

  17. Kapitany T, Meszaros K, Lenzinger E, Shindler SD, Barnas C, Fuchs K, Sieqhart W, Aschauer HN, Kasper S. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr. Res. 1998;32:101-6.

  18. Topic E, Stefanovic M, Ivanisevic AM, Blazinic F, Culav J, Skocilic Z. CYP2D6 genotyping in patients on psychoactive drug therapy. Clin. Chem. Lab. Med. 2000; 38: 921-7.

  19. De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry. 2005;66: 15-27.

  20. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenic in relation to CYP2D6 genotype. Br. J. Psychiatry.1997;170: 23-6.

  21. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacol.1997;131: 174-9.

  22. Arthur H, Dahl ML, Siwers B, Sjöqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J. Clin. Psychopharmacol.1995;15: 211-6.

  23. Baumann P, Broly F, Kosel M, Eap CB. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2D6 genotyping. Pharmacopsychiatry.1998;31: 72.

  24. Bertilsson L, Dahl ML, Sjöqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqrist E, Ingelman-Sundberg M. Molecular basis for rational megaprescribing in ultrarapid hydroxylation of debrisoquine. Lancet.1993;341:63.

  25. Kawanishi C, Furuno T, Kishida I, Matsumura T, Kosaka K. A patient with treatment-resistant schizophrenia and cytochrome P450IID6 gene duplication. Clin. Genet. 2002; 61:152-154.

  26. 26. Kawanishi C, Lundgren S, Agren H. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of no response. A pilot study. Eur. J. Clin. Pharmacol. 2004;59: 803-7

  27. Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. The pharmacogenomics journal. 2011;11(1):1-14.

  28. Fonne-Pfister R, Bargetzi MJ, Meyer UA. MPTP, the neurotoxin inducing Parkinson’s disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem. Biophys. Res. Commun. 1987;148:1144-50.

  29. Gilham DE, Cairins W, Paine MJ, Modi S, Paulson R, Roberts GC, Wolf CR. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human fetal and adult brain by in situ hybridization. Xenobiotica. 1997;27:111-25.

  30. Chinta SJ, Pai HV, Upadhya SC, Boyd MR, Ravindranath V. Constitutive expression and localization of the major drug metabolizing enzyme cytochrome P4502D in human brain. Brain Res. Mol. Brain Res. 2002;103:49-61.

  31. Hiroi T., Kishimoto W., Chow T., Imaoka S., Igarashi T., Funai Y. Progesterone oxidation by cytochrome P4502D isoforms in the brain. Endocrinology.2001;142: 3901-8.

  32. Schyman P, Lai W, Chen H, Wang Y, Shaik S. The directive of the protein: how does cytochrome P450 select the mechanism of dopamine formation? Journal of the American Chemical Society. 2011;133(20):7977-84.

  33. 33.Ingelman-Sundberg M, Persson A, Jukic MM. Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates. Pharmacogenomics. 2014;15(15):1841-4.

  34. Bromek E, Haduch A, Daniel WA. The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study. European journal of pharmacology.2010;626(2-3):171-8.

  35. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun.1998;249:838-43.

  36. Sindrup SH, Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF. Are poor metabolizers of spartine/debrisoquine less pain tolerant than extensive metabolizers? Pain.1993;53: 335-9.

  37. Dahl AA, Løwert A, Asserson S, Bjarking L, Berglund J, Kristensen F, et al. Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark. Hum Psychopharmacol 1998;13:509–11.

  38. Llerena A, Dorado P, Penas-Lledo EM, Caceres MC, De la Rubia A. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. The pharmacogenomics journal.2007;7(6):408-10.

  39. Jönsson EG, Dahl ML, Roh HK, Jerling M, Sedvall GC. Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia. Psychiatr Genet 1998;8:25–8.

  40. Chen CH, Hung CC, Wei FC, Koong FJ. Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan. Psychiatr Genet. 2001;11:153–5.

  41. Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Gesteira A, Barros F, Carracedo A, Hutz MH. Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians. Pharmacogenomics. 2009;10(9):1457-66.

  42. Alvarez S, Mas S, Gasso P, Bernardo M, Parellada E, Lafuente A. Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes. Fundam.Clin.Pharmacol. 2010; 24:741–7.




2020     |     www.medigraphic.com